- Home
- ACAD vs TFSL Comparison
ACAD vs TFSL Comparison
Compare ACAD & TFSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- TFSL
- Stock Information
- Founded
- ACAD 1993
- TFSL 1938
- Country
- ACAD United States
- TFSL United States
- Employees
- ACAD N/A
- TFSL N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- TFSL Savings Institutions
- Sector
- ACAD Health Care
- TFSL Finance
- Exchange
- ACAD Nasdaq
- TFSL Nasdaq
- Market Cap
- ACAD 4.0B
- TFSL 3.6B
- IPO Year
- ACAD 2004
- TFSL 2007
- Fundamental
- Price
- ACAD $25.74
- TFSL $13.75
- Analyst Decision
- ACAD Buy
- TFSL Hold
- Analyst Count
- ACAD 20
- TFSL 1
- Target Price
- ACAD $28.63
- TFSL $15.00
- AVG Volume (30 Days)
- ACAD 2.0M
- TFSL 312.1K
- Earning Date
- ACAD 08-06-2025
- TFSL 07-30-2025
- Dividend Yield
- ACAD N/A
- TFSL 8.53%
- EPS Growth
- ACAD 615.00
- TFSL 3.58
- EPS
- ACAD 1.33
- TFSL 0.29
- Revenue
- ACAD $1,018,885,000.00
- TFSL $308,625,000.00
- Revenue This Year
- ACAD $13.28
- TFSL $6.24
- Revenue Next Year
- ACAD $10.88
- TFSL $3.83
- P/E Ratio
- ACAD $18.70
- TFSL $45.69
- Revenue Growth
- ACAD 14.41
- TFSL 1.03
- 52 Week Low
- ACAD $13.40
- TFSL $11.29
- 52 Week High
- ACAD $25.88
- TFSL $15.00
- Technical
- Relative Strength Index (RSI)
- ACAD 66.52
- TFSL 70.92
- Support Level
- ACAD $24.47
- TFSL $12.96
- Resistance Level
- ACAD $25.88
- TFSL $13.24
- Average True Range (ATR)
- ACAD 0.71
- TFSL 0.18
- MACD
- ACAD 0.00
- TFSL 0.08
- Stochastic Oscillator
- ACAD 94.62
- TFSL 96.89
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About TFSL TFS Financial Corporation
TFS Financial Corp is the holding company for the Third Federal Savings and Loan Association of Cleveland. The company's ownership in the savings and loan association is its primary business activity. The association's principal business consists of originating and servicing residential real estate mortgage loans and attracting retail savings deposits. It does so by offering products with competitive rates and yields. The company also operates Third Capital, a wholly owned subsidiary that serves as a holding company or as an investor in vehicles such as private equity funds. Third Capital has interests in lease transactions of commercial buildings, title agencies providing escrow and settlement services, and reinsurance of private mortgage insurance on residential loans.